Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial
机构：[1]Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai, Peoples R China[2]Hunan Prov Canc Hosp, Changsha, Peoples R China[3]Yangzhou Univ, Jiangsu Subei Peoples Hosp, Northern Jiangsu Peoples Hosp, Yangzhou, Peoples R China[4]Jilin Canc Hosp, Changchun, Peoples R China[5]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China[6]USTC, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China[7]Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China[8]Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[9]Yunnan Canc Hosp, Kunming, Peoples R China[10]Kunming Med Univ, Affiliated Hosp 3, Kunming, Peoples R China[11]Yunnan Canc Ctr, Kunming, Peoples R China[12]UESTC, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Sch Med, Chengdu, Peoples R China四川省肿瘤医院[13]Anhui Chest Hosp, Hefei, Peoples R China[14]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China[15]Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China[16]Shaaxi Provincal Canc Hosp, Xian, Peoples R China[17]Hubei Canc Hosp, Wuhan, Peoples R China[18]Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Peoples R China江苏省人民医院[19]Chongqing Univ, Canc Hosp, Chongqing, Peoples R China[20]Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
出处：
ISSN：
摘要：
Background: In the phase III CameL-sq trial, Cam-chemo as 1L
treatment significantly prolonged PFS vs placebo (PBO)-chemo in
patients (pts) with advanced sqNSCLC. Here, we report updated
outcomes 5 y after enrollment of the last pt.
第一作者机构：[1]Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou C.,Ren S.,Chen J.,et al.Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial[J].JOURNAL OF THORACIC ONCOLOGY.2025,20(3):
APA：
Zhou, C.,Ren, S.,Chen, J.,Xu, X.,Cheng, Y....&Lu, X..(2025).Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial.JOURNAL OF THORACIC ONCOLOGY,20,(3)
MLA：
Zhou, C.,et al."Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial".JOURNAL OF THORACIC ONCOLOGY 20..3(2025)
医学